Full Text View
Tabular View
No Study Results Posted
Related Studies
OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
This study has been completed.
Study NCT00130403   Information provided by Sanofi

First Received on August 12, 2005.   Last Updated on January 10, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis, Postmenopausal
Additional conditions recognized in this trial
Osteoporosis
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Interventions listed in this trial
risedronate sodium
Additional drug interventions recognized in this trial
Alendronate
Etidronic Acid
Risedronic acid
Teriparatide
More general drug interventions related to this trial
Bone Density Conservation Agents
Calcium Channel Blockers
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Sanofi
Procter and Gamble


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services